Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. develops and commercializes medical technology and healthcare services for breathing-related sleep disorders, including obstructive sleep apnea and snoring associated with dentofacial abnormalities. Its Complete Airway Repositioning and Expansion (CARE) oral devices have FDA 510(k) clearances for adult OSA patients across severity levels and for moderate-to-severe OSA in children ages 6 to 17.
Company news commonly covers financial results, sleep testing services, treatment-center activity, and the integration of The Sleep Center of Nevada operating assets. Updates also address the shift toward a medical-affiliation distribution model, payer-network status for supported professional practices, collaborations for airway and sleep technologies, and capital actions such as warrant exercises and private placements.
Vivos Therapeutics (NASDAQ: VVOS) announced the opening of its first Pneusomnia clinic in Del Mar, California, aimed at addressing sleep apnea through the Vivos System. This integrated medical-dental center, led by Dr. Mimi Guarneri, will provide innovative, non-invasive treatments for mild-to-moderate obstructive sleep apnea (OSA). The Vivos System is designed to treat the root causes of sleep apnea without requiring lifelong intervention. Additional clinics are planned across the U.S., enhancing patient access to vital screenings and treatments.
Vivos Therapeutics (NASDAQ: VVOS) announced its participation in the 33rd Annual ROTH Conference from March 15-17, 2021. CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew will present on March 16 at 11:30 am ET. Investors can register for the presentation through a provided link and a replay will be available on the company's website. Vivos specializes in innovative treatments for sleep-disordered breathing, particularly mild to moderate obstructive sleep apnea, using its Vivos System that has helped over 18,000 patients globally.
Vivos Therapeutics (NASDAQ: VVOS) has launched VivoScore, a home sleep apnea test utilizing advanced cardiopulmonary technology by SleepImage. This single-sensor device connects to a mobile app, facilitating clinical-grade sleep apnea diagnosis. The pilot study indicated that 56% of tested patients had OSA, with 50% pursuing treatment through the Vivos System. This innovation is expected to lower costs and enhance diagnosis accessibility for untreated sleep apnea patients, addressing a market of roughly 1 billion individuals worldwide. VivoScore is anticipated to significantly boost patient enrollment and revenue for Vivos Therapeutics.
Vivos Therapeutics (NASDAQ: VVOS) announced the formation of a Clinical Advisory Board to enhance the adoption of its innovative treatments for obstructive sleep apnea (OSA), which affects 1 billion people worldwide. The board comprises distinguished experts from sleep medicine and dentistry, bringing decades of experience to ensure the Vivos System remains a leading non-surgical treatment. This move aims to strengthen Vivos' market position and drive further commercial success, leveraging the expertise of its members.
Vivos Therapeutics (NASDAQ: VVOS) has launched its new patient management software, AireO2, aimed at improving the diagnosis and treatment of obstructive sleep apnea (OSA). With around 1 billion people affected by OSA, the software enhances healthcare professionals’ billing services and operational efficiency. CEO Kirk Huntsman emphasized that AireO2 will help manage more patients effectively. The platform is poised to drive revenue for Vivos beyond its existing services, potentially addressing the needs of OSA-focused healthcare providers.
Vivos Therapeutics announced the closing of its IPO, issuing 4,025,000 shares at $6.00 each, yielding gross proceeds of $24.15 million. The offering included 3,500,000 initial shares plus 525,000 additional shares from underwriters’ options. Roth Capital Partners led the offering, with Craig-Hallum Capital Group and National Securities Corporation as co-managers. The SEC had declared the registration effective on December 10, 2020, with a final prospectus filed on December 14, 2020. Vivos specializes in non-invasive solutions for sleep disordered breathing.